
Company valuation, historical trends, and peer comparisons.
According to ImmunityBio, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.30B. This represents a change of 53.07% compared to the average of 6.07B of the last 4 quarters.
The mean historical Enterprise Value of ImmunityBio, Inc. over the last ten years is 2.37B. The current 9.30B Enterprise Value has changed 292.24% with respect to the historical average. Over the past ten years (40 quarters), IBRX's Enterprise Value was at its highest in in the June 2026 quarter at 9.94B. The Enterprise Value was at its lowest in in the December 2018 quarter at 367.14M.
Average
2.37B
Median
2.38B
Minimum
367.14M
Maximum
5.35B
Discovering the peaks and valleys of ImmunityBio, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 295.38%
Maximum Annual Enterprise Value = 5.35B
Minimum Annual Increase = -73.83%
Minimum Annual Enterprise Value = 367.14M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 2.61B | 21.68% |
| 2024 | 2.15B | -28.82% |
| 2023 | 3.01B | 13.90% |
| 2022 | 2.65B | -6.52% |
| 2021 | 2.83B | -47.07% |
| 2020 | 5.35B | 268.45% |
| 2019 | 1.45B | 295.38% |
| 2018 | 367.14M | -73.83% |
| 2017 | 1.40B | -25.36% |
| 2016 | 1.88B | -65.71% |
The current Enterprise Value of ImmunityBio, Inc. (IBRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
2.59B
5-year avg
2.65B
10-year avg
2.37B
ImmunityBio, Inc.’s Enterprise Value is greater than Immunocore Holdings plc (1.50B), less than BioNTech SE (10.17B), greater than Iovance Biotherapeutics, Inc. (3.50B), greater than Vir Biotechnology, Inc. (1.69B), less than Moderna, Inc. (89.07B), greater than Legend Biotech Corporation (3.55B), greater than Nkarta, Inc. (158.17M), greater than Immatics N.V. (741.26M), greater than Atara Biotherapeutics, Inc. (88.82M), greater than Allogene Therapeutics, Inc. (411.77M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 1.50B | $1.55B | |
| 10.17B | $22.02B | |
| 3.50B | $3.56B | |
| 1.69B | $1.88B | |
| 89.07B | $89.51B | |
| 3.55B | $3.94B | |
| 158.17M | $109.59M | |
| 741.26M | $1.07B | |
| 88.82M | $82.16M | |
| 411.77M | $380.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunityBio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ImmunityBio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ImmunityBio, Inc.'s Enterprise Value?
What is the highest Enterprise Value for ImmunityBio, Inc. (IBRX)?
What is the 3-year average Enterprise Value for ImmunityBio, Inc. (IBRX)?
What is the 5-year average Enterprise Value for ImmunityBio, Inc. (IBRX)?
How does the current Enterprise Value for ImmunityBio, Inc. (IBRX) compare to its historical average?